Please login to the form below

Not currently logged in

UK Prix Galien opens for entries

Pharma R&D accolades will include a new real world evidence category

Prix Galien 2014 winner Novartis 
Pictured: Novartis pick up the 2014 Innovative Product award

Entries have opened for the 2016 UK Prix Galien Awards, which commend pharmaceutical research and development and celebrate outstanding efforts to improve the human condition through the development of novel, high-value medicines.

Established in 1970, the next outing for the bi-annual prizes will include a new real world evidence category, alongside their well-established accolades for innovative products and orphan product.

The 2014 UK Prix Galien was won by Bexserothe first ever vaccine to treat invasive meningococcal disease, and Sirturo, the first TB medication to be approved in four decades.

The Prix Galien is recognised in 17 countries across Europe and North America, with presences in emerging markets in Asia and Latin America expected soon. The UK Prix Galien franchise is now owned by ValueBase, whose experienced team has a long-standing affiliation with the awards. The 2016 UK judging panel is once again led by Professor Sir Michael Rawlins, chair of the MHRA and founding chair of NICE from 1999 to 2014.

Previous UK Prix Galien winners include well-known brands such as Viagra, Herceptin, Glivec, Xolair, Cervarix and Gardasil. More recent winners, such as Xarelto, Incivo and Victrelis, show how pharmaceutical innovation is helping to transform healthcare services and improve public health.

Registration for entries for the 2016 Awards will close on 29 February 2016, with final submissions due by 29 April 2016, as part of a process that culminates in a ceremony at the House of Commons in September 2016.

For further details on the awards and the entry process visit 

Article by
Dominic Tyer

8th December 2015

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company

Transforming healthcare through effective collaboration. Making work to feel proud of.

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...